In this webinar, you will learn:
- How AI and HDX-MS are applied in screening, epitope mapping, and selecting neutralizing antibodies against SARS-Cov-2.
- The predictive capabilities of AI computational modeling and its validation and refinement by high-resolution HDX-MS.
- How the integration of AI with HDX-MS informs antibody characterization for the accelerated development of therapeutic antibodies.
Abstract
Artificial intelligence (AI) and computational modeling have emerged as powerful tools for predicting antibody epitopes and structures, leveraging vast datasets and algorithms to simulate antibody-antigen interactions. This predictive capability is complemented by in vitro validation using hydrogen-deuterium exchange mass spectrometry (HDX-MS), enabling high-resolution epitope mapping and elucidating other structural details of antibody-antigen binding.
Here, we demonstrate the application of AI and HDX-MS in screening and characterizing neutralizing antibodies against SARS-CoV-2 from an antibody discovery campaign involving healthy, vaccinated donors.
Computational modeling was used to screen over 700 mAbs from the discovery campaign, selecting 16 mAbs for expression. This led to the identification of 12 binders, including 4 high-affinity binders and 1 cross-neutralizing antibody against several SARS-CoV-2 variants. HDX-MS epitope mapping confirmed the binding epitopes, providing crucial structural details on antibody-antigen interactions and revealing further insights into antibody function.
The integration of AI and HDX-MS facilitates comprehensive and precise antibody epitope mapping, enabling high-throughput screening and invaluable insights into antibody specificity and function.
Speaker Bios
Astrid Musnier, PhD
Co-Founder and Head of Biology
Astrid Musnier leads the biological R&D and is in charge of experimental validations of computer technologies at MAbSilico. She holds a doctorate in biology, has a strong expertise in protein interaction and GPCR, and has worked with Anne Poupon and Thomas Bourquard at the INRAE / CNRS laboratory. She worked at the Hunter College in New York to decipher the mechanism of action of FMRP, a protein involved in autistic fragile X syndrome before returning to France and co-founded MAbSilico.
Dominic Narang, PhD
Rapid Novor
Senior Scientist & Manager, HDX Services
Dominic leads the HDX-MS Epitope Mapping team at Rapid Novor, bringing seven-plus years of experience in mass spectrometry. He specializes in providing solutions to biotechnology and pharma companies for their drug discovery and development platforms using Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS), a powerful tool for characterizing antibody-antigen interactions.
Prior to joining Rapid Novor, Dominic held positions at prestigious academic and industrial settings, including the University of California – San Diego, York University, and Sanofi Pasteur – Toronto. He has a proven track record of successfully delivering numerous antibody characterization projects using HDX-MS.
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics